pharmaceutical investments

2+ articles

FDA Layoffs and Voucher Program Expiration Cast Shadow Over Rare Disease Drug Development

The FDA's pediatric priority review voucher program expired in December 2024, causing uncertainty for drug developers. Combined with FDA layoffs, this creates an investment risk in rare pediatric drug development. Smaller companies face significant challenges, and while reauthorization is expected before 2026, investor concerns have already inflated the voucher market's value.

Apr 23

FDA Layoffs and Voucher Program Expiration Cast Shadow Over Rare Disease Drug Development

Pfizer Sells 700 Million Haleon Shares, Pocketing $3.05 Billion!

In a strategic move, Pfizer has sold 700 million shares of Haleon, garnering $3.05 billion. This divestiture aligns with Pfizer's post-spinoff strategy and grants the pharma giant a substantial cash infusion for R&D and potential acquisitions. Meanwhile, Haleon's business remains steady, though its market valuation might see fluctuations from this block sale. Pfizer continues to streamline its operations post its consumer healthcare spinoff, paving the path for focused pharmaceutical advancements.

Jan 17

Pfizer Sells 700 Million Haleon Shares, Pocketing $3.05 Billion!